AlgiPharma has developed a novel low molecular weight alginate OligoG™ from seaweed that restores normal mucus function and makes chronic infections more susceptible to antimicrobial therapy. Airway mucus is a key protective barrier: OligoG™ facilitates the secretion and flow of airway mucus, preventing accumulation of stagnant mucus, and restoring barrier function. OligoG™ also disrupts biofilms and makes bacteria and fungi susceptible to lower concentrations of antibiotics, reducing persistent infections. These properties offer an innovative approach in the treatment of respiratory diseases that are associated with the accumulation or hyperviscous mucus and persistent infections. OligoG™ has shown promising effects in Cystic Fibrosis (CF). Commercialization in CF could generate peak annual sales of EUR 600 million. This reflects what can be achieved in other respiratory diseases, such as COPD, asthma, and infectious pneumonia, with sales > EUR 1 billion. The TRANSPIRE project aims to demonstrate superiority of OligoG versus placebo in a phase IIb double blinded multicenter clinical trial.